Hemab Therapeutics (NASDAQ:COAG) Price Target Raised to $60.00

Hemab Therapeutics (NASDAQ:COAG) had its target price raised by HC Wainwright from $52.00 to $60.00 in a research note issued to investors on Tuesday, MarketBeat reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Hemab Therapeutics’ Q4 2026 earnings at ($0.57) EPS, FY2026 earnings at ($3.19) EPS, FY2028 earnings at ($3.62) EPS, FY2029 earnings at ($3.60) EPS and FY2030 earnings at ($2.04) EPS.

Other analysts also recently issued research reports about the stock. Wall Street Zen upgraded shares of Hemab Therapeutics to a “hold” rating in a report on Saturday, May 9th. Evercore began coverage on shares of Hemab Therapeutics in a research note on Tuesday, May 26th. They set an “outperform” rating and a $50.00 price objective for the company. Zacks Research raised shares of Hemab Therapeutics to a “hold” rating in a research report on Wednesday, May 27th. Wedbush reissued an “outperform” rating and issued a $55.00 target price (up from $42.00) on shares of Hemab Therapeutics in a research note on Monday, July 13th. Finally, The Goldman Sachs Group began coverage on shares of Hemab Therapeutics in a report on Tuesday, May 26th. They set a “buy” rating and a $36.00 target price on the stock. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $51.40.

Hemab Therapeutics Price Performance

Shares of NASDAQ:COAG opened at $53.95 on Tuesday. The firm has a market capitalization of $2.52 billion and a price-to-earnings ratio of -2.25. The stock’s 50-day moving average price is $38.58. Hemab Therapeutics has a 12 month low of $23.00 and a 12 month high of $55.18.

Hemab Therapeutics (NASDAQ:COAG) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.17). As a group, research analysts predict that Hemab Therapeutics will post -3.09 EPS for the current year.

Insider Activity

In other news, major shareholder Ra Capital Management, L.P. acquired 61,523 shares of the company’s stock in a transaction dated Tuesday, June 16th. The shares were bought at an average price of $24.98 per share, for a total transaction of $1,536,844.54. Following the completion of the purchase, the insider directly owned 6,444,637 shares of the company’s stock, valued at approximately $160,987,032.26. This trade represents a 0.96% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders have purchased a total of 72,467 shares of company stock worth $1,809,595 in the last 90 days.

Key Hemab Therapeutics News

Here are the key news stories impacting Hemab Therapeutics this week:

• Positive Sentiment: HC Wainwright maintains a Buy rating and raises several long-term estimates. The firm increased its Q4 2026 EPS estimate to $(0.57) from $(0.60), FY2028 to $(3.62) from $(3.63), FY2029 to $(3.60) from $(3.89), and FY2030 to $(2.04) from $(2.44). These revisions suggest analysts expect Hemab’s losses to narrow more quickly in the later forecast period. HC Wainwright Forecasts Strong Price Appreciation for Hemab Therapeutics
• Positive Sentiment: The $60 price target supports the bullish case. HC Wainwright’s target is above recent trading levels and may be encouraging investors who expect progress in Hemab’s clinical pipeline and eventual commercialization to support valuation.
• Neutral Sentiment: Hemab reported second-quarter 2026 results and provided a corporate update. The company’s quarterly loss of $0.80 per share was wider than the $0.63 analyst consensus, but investors may also be focusing on pipeline and business updates rather than near-term earnings because the company remains development-stage. Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
• Negative Sentiment: One estimate revision highlights ongoing cash-burn concerns. HC Wainwright lowered its FY2026 EPS forecast to $(3.19) from $(3.12), while the broader consensus calls for a $(2.89) loss for the current year. Hemab’s negative earnings and the recent quarterly miss remain risks, particularly if development expenses continue rising.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.